Susquehanna Fundamental Investments’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Susquehanna Fundamental Investments’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-42,353	Closed	-$45.3K	–	355
2023 Q3	$45.3K	Hold	42,353	–	–	﹤0.01%	353
2023 Q2	$110K	Hold	42,353	–	–	﹤0.01%	603
2023 Q1	$173K	Sell	42,353 -1,604	-4%	-$7.41K	﹤0.01%	880
2022 Q4	$221K	Buy	+43,957	New	+$276K	﹤0.01%	1055

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna Fundamental Investments's NGM Position: Q4 2023 in Review

Susquehanna Fundamental Investments sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2023, closing a stake of 42,353 shares — an estimated $45.3K sold.

Susquehanna Fundamental Investments first reported a position in NGM in Q4 2022 and held it in 4 quarters. The position peaked at $221K in Q4 2022. 83 funds tracked by Wall St. Rank hold NGM as of Q4 2023.

Susquehanna Fundamental Investments reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Susquehanna Fundamental Investments sold 42,353 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $45.3K.
Susquehanna Fundamental Investments first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 4 quarters.
Susquehanna Fundamental Investments's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $221K in Q4 2022.
83 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2023, filed 14 Feb 2024.